Genetic Immunity, a leader in plasmid DNA-based immunotherapies, and VectorBuilder, a global specialist in gene delivery solutions, announced a strategic partnership to advance Genetic Immunity's ...

The new Dogma meets Thomas Kuhn’s definition of a paradigm shift. The DNA/RNA Dogma is sufficiently unprecedented to attract ...

Viral Vector Development MarketThe Viral Vector Development Market is set for impressive growth, with its valuation expected to rise from USD 730.7 million in 2023 to USD 4.1 billion by 2033, ...

at 07:05 Genetic Immunity (GI) Leverages VectorBuilder Partnership to Power Phase 3 HIV Vaccine Trials Genetic Immunity, a leader in plasmid DNA-based immunotherapies, and VectorBuilder, a global ...

Thanks to technological advancements in nucleic acid sequencing and the shift toward molecular research and personalized medicine, omics approaches have become increasingly important in studying the ...

This important study by Bi and colleagues employed a clever genetics screen to uncover the role of the GidB rRNA methylase in translation fidelity, under certain conditions, in Mycobacterium smegmatis ...

Vasomune Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of AV-001 for the treatment of diseases associated with vascular dysfunction, announced today that ...